CureC9 and BrainXell Partner to Advance ALS and FTD Research Through Patient-Driven Innovation
MADISON, Wis., Aug. 6, 2026 /PRNewswire/ -- CureC9, a patient-driven initiative dedicated to accelerating treatments for C9orf72-associated amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), has partnered with BrainXell, Inc. to expand access to high-quality,...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.